D
David Andre Baptiste Maussang-Detaille
Publications - 6
Citations - 9
David Andre Baptiste Maussang-Detaille is an academic researcher. The author has contributed to research in topics: Antibody & Epitope. The author has an hindex of 2, co-authored 6 publications receiving 7 citations.
Papers
More filters
Proceedings ArticleDOI
Abstract LB-261: Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer
Cecile Geuijen,Eric Rovers,Tristan Gallenne,David Andre Baptiste Maussang-Detaille,Arjen Kramer,Nellie Nieuwenhuizen,Carina Clements,Katinka van Zoest,Roy Nijhuis,Therese Visser,Renate den Blanken-Smit,Willem Bartelink,Vanessa Zondag-van der Zande,Linda Kaldenberg,Pieter-Fokko van Loo,Rob Roovers,Robert Doornbos,Leo S. Price,Stefan R. Braam,Setareh van Driel,Lex Bakker,Ton Logtenberg,John de Kruif,Mark Throsby +23 more
TL;DR: The unique simultaneous targeting of MCLA-128 to HER2 and HER3 on HER2-overexpressing breast cancer cells leads to severe impairment of PI3K signaling and reduced cell growth whereas proliferation of primary cardiomyocytes is unaffected.
Proceedings ArticleDOI
Abstract 32: Preclinical evaluation of MCLA-158: A bispecific antibody targeting LGR5 and EGFR using patient-derived colon carcinoma organoids
Rob Roovers,Bram Herpers,Mark James,Berina Eppink,Carme Cortina,David Andre Baptiste Maussang-Detaille,Ingrid Kolfschoten,Sylvia Boy,Marc van de Wetering,Wim de Lau,Robert Doornbos,Kuan Yan,Lucia Salinaro,Lex Bakker,John de Kruif,Hans Clevers,Robert P. de Vries,Eduard Batlle,Leo S. Price,Mark Throsby +19 more
TL;DR: Preclinical data suggest MCLA-158 could benefit patients with metastatic CRC and warrant clinical evaluation, and demonstrates superior activity compared to reference antibodies in both in vitro and in vivo tumor organoid based assays regardless of KRAS status.
Proceedings ArticleDOI
Abstract 33: The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis
David Andre Baptiste Maussang-Detaille,Camilla De Nardis,Linda Johanna Aleida Hendriks,Carina Bartelink-Clements,Eric Rovers,Tristan Gallenne,Robert Doornbos,Lex Bakker,John de Kruif,Ton Logtenberg,Piet Gros,Cecile Geuijen,Mark Throsby +12 more
TL;DR: The potent anti-proliferative activity of MCLA-128 in vitro and in vivo supports the clinical development of this bispecific HER2xHER3 antibody in HRG-driven tumors.
Patent
Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
TL;DR: In this paper, the authors proposed a method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an ErbB-2/3 positive tumor.
Patent
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
TL;DR: In this article, the authors proposed a method of treating a subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbBB-3 bispecific antibody and a therapeutic effect of an endocrine therapy drug.